Supernus Pharmaceuticals, Inc.SUPNNASDAQ
LOADING
|||
Revenue Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year revenue growth rate
Latest
16.11%
↑ 234% above average
Average (39q)
4.82%
Historical baseline
Range
High:33.43%
Low:-26.27%
CAGR
+1.1%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 16.11% |
| Q2 2025 | 10.43% |
| Q1 2025 | -13.97% |
| Q4 2024 | -0.87% |
| Q3 2024 | 4.37% |
| Q2 2024 | 17.18% |
| Q1 2024 | -12.58% |
| Q4 2023 | 6.78% |
| Q3 2023 | 13.51% |
| Q2 2023 | -11.84% |
| Q1 2023 | -8.11% |
| Q4 2022 | -5.65% |
| Q3 2022 | 4.29% |
| Q2 2022 | 11.50% |
| Q1 2022 | -4.11% |
| Q4 2021 | 7.13% |
| Q3 2021 | 5.05% |
| Q2 2021 | 7.94% |
| Q1 2021 | -8.79% |
| Q4 2020 | -7.46% |
| Q3 2020 | 22.41% |
| Q2 2020 | 33.43% |
| Q1 2020 | -5.45% |
| Q4 2019 | -1.66% |
| Q3 2019 | -2.44% |
| Q2 2019 | 22.49% |
| Q1 2019 | -26.27% |
| Q4 2018 | 12.56% |
| Q3 2018 | 3.47% |
| Q2 2018 | 10.07% |
| Q1 2018 | 2.25% |
| Q4 2017 | 10.00% |
| Q3 2017 | 6.03% |
| Q2 2017 | 31.70% |
| Q1 2017 | -7.69% |
| Q4 2016 | 9.79% |
| Q3 2016 | 12.67% |
| Q2 2016 | 17.05% |
| Q1 2016 | 0.98% |
| Q4 2015 | 10.55% |